930 results about "Fatty liver" patented technology

The present disclosure provides a class of compounds represented by formula (I '), or tautomers, stereoisomers or pharmaceutically acceptable salts thereof. The compound disclosed by the invention has a relatively strong agonistic effect on GLP-1R, can be used for treating diseases such as diabetes mellitus, metabolism-related fatty liver diseases, Alzheimer's disease and the like or has an effect of reducing weight. # imgabs0 #

The invention relates to the technical field of grease chemistry, in particular to a preparation method and application of diglyceride oil capable of preventing and treating fatty liver. The preparation method comprises the following steps: (1) mixing raw material oil, water, glycerol and a lipase preparation for catalytic reaction to obtain a product 1; the raw material oil comprises 0.1-8 parts of sea buckthorn seed oil, 0.1-8 parts of acer truncatum seed oil, 60-90 parts of low erucic acid rapeseed oil, 15-35 parts of corn oil and 10-25 parts of peanut oil; the lipase preparation is aspergillus niger lipase and rhizopus niger lipase; (2) performing five-stage molecular distillation on the product 1 to obtain a product 2; and (3) decoloring and deodorizing the product 2 to obtain the product. The diglyceride oil prepared by the invention has excellent effects of preventing and treating fatty liver.

The invention relates to application of fermentation lactobacillus mucus LFPerfectuus001 in preparation of a product for improving metabolic syndrome caused by high-fat and high-sugar diet, and belongs to the technical field of microorganisms. The invention provides application of fermented lactobacillus mucus LFPerfecus001 in preparation of a product for improving metabolic syndrome, the fermented lactobacillus mucus LFPerfecus001 is preserved in Guangdong Microbial Culture Collection Center on April 13, 2022, and the preservation number is GDMCC No: 62335. The invention further provides a preparation method of the fermented lactobacillus mucus LFPerfecus001. Animal experiments report that the fermented lactobacillus mucus LFPerfectus001 has the effects of reducing fat, increasing muscle, improving obesity, hyperglycemia, insulin resistance, dyslipidemia, hyperuricemia and fatty liver for the first time, and can well improve metabolic syndrome caused by high fat and high glucose.

Provided are a compound represented by formula (I'), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof. The compound represented by formula (I') has a strong agonistic effect on GLP-1R, and can treat diseases such as diabetes, metabolic-associated fatty liver diseases, and Alzheimer's disease, or has a weight loss effect.

The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.

The invention discloses pediococcus acidilactici and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici is pediococcus acidilactici Mei.1103.1, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.32564, the preservation date is November 11, 2024, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1 is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1. The invention also provides application of the fermented dry rice flour in preparation of products for reducing uric acid, preventing / treating hyperuricemia, regulating immunity, preventing / treating kidney injury and preventing / treating fatty liver and fermented dry rice flour. The bacterium can reduce uric acid and relieve hyperuricemia; regulating blood fat; kidney and liver injuries caused by hyperuricemia are repaired; the content of volatile flavor compounds in the fermented dry rice flour is increased.

A GLP-1-Fc-FGF21 double-target fusion protein composition and the use thereof. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by means of adding the buffer solution, the generation of visible particles can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein is improved, so that the shelf life of a product can be prolonged. The composition can be used for treating and / or preventing metabolic diseases, such as diabetes, hyperlipidemia, obesity and diseases related to fatty liver.

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici ZJUIDS13 in improvement of liver diseases, including improvement of alcoholic liver diseases and improvement of fatty liver diseases related to metabolic dysfunction. The pediococcus acidilactici ZJUIDS13 has relatively strong capability of protecting liver injury induced by alcohol, and can improve the states of liver injury and lipid metabolism disorder caused by high fat diet.

The invention discloses a steroid compound as well as a preparation method and application thereof. The invention specifically discloses a steroid compound with a structure as shown in a formula I and the like or a pharmaceutically acceptable salt of the steroid compound. The compound provided by the invention has SREBP pathway inhibitory activity, and can be used for preventing and / or treating obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, skin injury and other diseases. # imgabs0 #

The invention discloses a self-assembled nano material for targeting liver and improving fatty liver as well as a preparation method and application of the self-assembled nano material, and belongs to the technical field of preparation of novel nano materials. According to the invention, a self-assembled nano material is formed by MOF, thyroid hormone and an ASGR1 antibody. The MOF material has good preservation performance, can effectively remove active oxygen in cells and intercellular substances, and reduces damage of the active oxygen to liver cells. The thyroid hormone is gathered in the MOF, the thyroid hormone can be accurately released after the MOF is targeted to the liver, the effect of the thyroid hormone on relieving the fatty liver degree is efficiently achieved, and toxic and side effects of the thyroid hormone on other organs of the whole body are effectively avoided. The surface of MOF is modified with an ASGR1 antibody, the antibody can accurately target the self-assembled nano-material to the surface of a liver cell membrane, and the ASGR1 antibody can effectively inhibit ASGR1 on the surface of the liver cell membrane, so that the self-assembled nano-material can effectively promote discharge of cholesterol in cells.

The invention relates to application of mouse combined lactobacillus. According to the application disclosed by the invention, the lactobacillus murins DSM 28683 can be applied to the preparation of a product for treating type 2 diabetes mellitus or a product for reducing body fat. A T2D mouse is subjected to intragastric administration by using the Ligilbacillus murins DSM 28683, and it is found that the Ligilbacillus murins DSM 28683 can significantly improve metabolism of the T2D mouse, effectively improve insulin sensitivity of the T2D mouse, reduce body weight and improve fatty liver, and has a good application prospect in treatment of type 2 diabetes mellitus.

The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.

Disclosed are methods and uses for treating a subject having a condition selected from liver disease, Cushing's syndrome or Cushing's disease, cancer, infection, inflammation, cardiovascular, endocrine or kidney disease, and combinations thereof, or other disease that may thus be administered a drug that may cause hepatotoxicity, the methods and uses having no adverse effects on the liver. The liver diseases comprise fatty liver diseases, high-level liver enzyme can be effectively reduced, and good safety is achieved. The methods and uses include administering to a subject an effective amount of a selective non-steroidal glucocorticoid receptor modulator, such as relacan, including methods and uses for use in combination with other drugs, without adversely affecting liver enzyme levels or liver function. In embodiments, another drug may be a drug that may cause hepatotoxicity, such as a drug that inhibits the CYP3A enzyme, such as itraconazole or ketoconazole.

The invention relates to human hepatocyte organoids. In particular, hepatocyte organoids with modified genes involved in lipid homeostasis. The invention also relates to the use of such organoids for modelling diseases involving steatosis. Also included is the use of such organoids as models of fatty liver, such as caused by genetic as well as diet related fatty liver disorders and their use in discovery of novel drugs for treating fatty liver and related disorders. The invention further relates to agents for reducing steatosis in subjects having similar modifications as the hepatocyte organoids of the invention. The invention also relates to methods of reducing or preventing steatosis, treating or preventing cardiovascular disease; treating or preventing NAFLD, and preventing and / or reducing the risk of NASH and / or cirrhosis by increasing FADS2 activity in a subject. Also included is a FADS2 agonist, such as a small molecule, nucleic acid or polypeptide for use in said methods.

The invention discloses application of Osge as a molecular target to preparation of a medicine for preventing and / or treating fatty liver. According to the invention, the key effect of Osge as a therapeutic target in the treatment of fatty liver diseases caused by high fat diet is confirmed for the first time and is verified in a mouse model, and a method of overexpressing Osge through virus transfection proves that lipid deposition in liver tissues can be effectively reduced and liver balloon-like degeneration can be relieved by improving the expression level of Osge in the liver, so that the fatty liver diseases caused by high fat diet can be effectively treated. The accumulation of lipid droplets is reduced. The invention shows that Osge can be used as a new molecular target for preventing and treating fatty liver, and has important clinical application value in the aspect of treating metabolism-related fatty liver diseases.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.

Disclosed are a steroid compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof. The compound has SREBP pathway inhibitory activity, and can be used for preventing and / or treating diseases such as obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, and skin injury.

The invention relates to a GLP-1-Fc-FGF21 double-target fusion protein composition and an application thereof. The composition is prepared from the GLP-1-Fc-FGF21 fusion protein and a buffer solution. According to the composition disclosed by the invention, by adding the buffer solution, the generation of visible foreign matters can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein can be improved, so that the shelf life of the product can be prolonged, and the composition disclosed by the invention can be used for treating and / or preventing metabolic diseases, such as diabetes mellitus, hyperlipidemia, obesity and fatty liver related diseases.

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention discloses a lactobacillus mucus fermentation strain and application thereof, the lactobacillus mucus fermentation strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on February 21, 2025, and the preservation number is GDMCCNO: 65936. The feruloyl esterase is separated and screened from white sour soup in Kailing in southeast of Guizhou province, has feruloyl esterase activity, and shows good blood fat reducing and fatty liver treating capabilities in a HepG2 high-fat cell model and a high-fat zebra fish model. The compound has a good prospect in the development of products for preventing or treating hyperlipidemia and fatty liver and relieving obesity.

The invention discloses a multi-classification auxiliary prediction method and system for metabolism-related fatty liver diseases, electronic equipment and a storage medium, belongs to the field of medical data processing, and is used for solving the problem that a traditional MAFLD binary prediction model cannot fully reflect continuous pedigree of disease severity. The method comprises the following steps: acquiring clinical data related to classification prediction of metabolism-related fatty liver diseases; performing label coding, missing value filling and feature screening on the clinical data; and inputting the screened features into a TabNet classification model optimized by a particle swarm algorithm, and outputting a risk classification result of the metabolism-related fatty liver disease. According to the method, the severity of the fatty liver can be more accurately evaluated, the liver health condition of a patient is comprehensively reflected, and more accurate treatment guidance is provided for clinical diagnosis.

The invention relates to the technical field of drugs for gene therapy, in particular to application of CAP-Gly functional peptide in preparation of drugs for treating fatty liver. The invention provides application of a CAP-Gly functional peptide or a reagent for improving the expression quantity of the CAP-Gly functional peptide in preparation of a medicine for treating fatty liver. The amino acid sequence of the CAP-Gly functional peptide is shown as SEQ ID NO.23. The invention further provides a preparation method of the CAP-Gly functional peptide. The invention finds that the overexpression of the KIF13B protein or the CAP-Gly functional peptide thereof in mice can effectively reduce lipid accumulation in liver cells and increase phosphorylation of protein kinase alpha activated by adenosine monophosphate, and provides a new target and a new strategy for precise treatment of patients with fatty liver (especially metabolism-related fatty liver diseases) clinically.

The invention provides a 1, 4-polyisoprene dispersion system, a pharmaceutical active component and application of the 1, 4-polyisoprene dispersion system and the pharmaceutical active component. The dispersion system keeps stable in a gastric acid environment of mammals, does not separate out 1, 4-polyisoprene clots, has no oral toxicity to mammals, and does not contain sensitizers; and the 1, 4-polyisoprene dispersion system comprises a 1, 4-polyisoprene solution dispersion system and a 1, 4-polyisoprene emulsion dispersion system. The 1, 4-polyisoprene dispersion system provided by the invention can be used as an active pharmaceutical ingredient for preparing drugs for treating chronic metabolic diseases including atherosclerotic cardiovascular and cerebrovascular diseases, type 2 diabetes, hypercholesteremia, hypertriglyceridemia, fatty liver, colitis, obesity and polycystic ovarian syndrome.

The invention provides a rice bran fatty alkanol composition for reducing fat and losing weight and a preparation method of the rice bran fatty alkanol composition. The rice bran fatty alkanol composition for reducing fat and losing weight is composed of rice bran fatty alkanol and soybean sterol, and the rice bran fatty alkanol accounts for 5-30% of the mass of the composition. By optimizing the fingerprint spectrum of rice bran fatty alkanol, the composition proportion of higher fatty alkanol is effectively improved, the lipid-lowering, weight-losing and liver-protecting effects can be effectively improved, the lipid-lowering, weight-losing and liver-protecting effects are greatly improved by matching with soybean sterol, and a tablet containing the composition is further developed. The obtained lipid-lowering weight-losing liver-protecting tablet is safe and free of side effects, and can be eaten for a long time to prevent obesity and fatty liver.

A method is provided for treating or preventing alcohol dependence and / or an alcohol associated disease or condition. Such a method includes administrating a pharmaceutical composition comprising an effective amount of a compound having formula (I):or a hydrates, a solvate, a pharmaceutically acceptable salt, a prodrug, or a complex thereof to a subject in need thereof. For example, (3S, 4R)-3-((R)-(1-hydroxy-ethyl)-4-((R)-[1-methyl-2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-azetidin-2-one (MC-100093) is an exemplary compound. The composition can be used to prevent or treat alcohol dependence, attenuate alteration in glutamate transporters, reduce alcohol associated neuroinflammation, and treat or prevent alcohol associated fatty liver diseases.

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

The invention discloses application of vanillyl alcohol in preparation of medicines for preventing and treating fatty liver, obesity or diabetes, and belongs to the technical field of medicines. The invention is implemented in vitro and in vivo, and aims to solve the problem of lack of low-toxicity natural small molecule drugs for effectively preventing and treating fatty liver, obesity or diabetes at present. The embodiment of the invention proves that the vanillyl alcohol can obviously reduce high-fat diet induced mouse fat deposition, reduce in-vivo and in-vitro liver TG content and lipid droplet accumulation, enhance glucose tolerance of the high-fat diet induced mouse and improve insulin resistance of the high-fat diet induced mouse. As a natural antioxidant, vanillyl alcohol has an obvious relieving effect on energy metabolism disorder and oxidative stress induced by high fat. As a low-toxicity natural small molecule, vanillyl alcohol can improve glucose and lipid metabolism disorder induced by high fat, is low in price, and has application value in preparation of medicines for preventing and treating fatty liver, obesity or diabetes mellitus.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

The invention relates to the technical field of liver disease prediction, in particular to a metabolism-related fatty liver disease intelligent prediction method and system and a storage medium. The method comprises the following steps: collecting multi-source data, respectively obtaining basic demographic information, laboratory indexes and prediction indexes, and extracting quantitative and qualitative tongue picture parameters; performing variable screening on the tongue picture parameters and the clinical indexes, and determining key prediction variables; obtaining a key variable value according to the key prediction variable, obtaining a prediction result of the occurrence risk of the metabolism-related fatty liver disease, and outputting the prediction result; the system comprises a multi-source data acquisition module, a variable screening module and a prediction result acquisition module. By means of the mode, the intelligent tongue picture parameters and the clinical indexes are fused, and the effect of early prediction of the metabolism-related fatty liver diseases is achieved.